Annual report pursuant to Section 13 and 15(d)

License Agreements, Clinical Research Support Agreements and Sponsored Research Agreements (Details Textual)

v3.8.0.1
License Agreements, Clinical Research Support Agreements and Sponsored Research Agreements (Details Textual) - USD ($)
1 Months Ended 10 Months Ended 12 Months Ended
Jul. 03, 2017
Nov. 20, 2017
May 31, 2017
Mar. 31, 2017
Mar. 17, 2017
Feb. 28, 2017
Oct. 31, 2016
Apr. 30, 2015
Mar. 31, 2015
Dec. 31, 2015
Dec. 31, 2017
Dec. 31, 2016
Nov. 28, 2017
Jul. 31, 2016
Research And Development Expense, Sponsored Research Payment                         $ 800,000  
Research and Development Expense                     $ 100,000      
Common Stock, Shares, Outstanding                     25,236,255 15,165,244    
Professional Fees                     $ 120,000 $ 120,000    
Stock Issued During Period, Value, Purchase of Assets                   $ 147,000 $ 1,682,000      
Proceeds from Issuance of Private Placement             $ 10,000,000              
Common Stock, Shares Authorized                     50,000,000 50,000,000    
Psca Technology License [Member]                            
Payment Of Upfront Fees     $ 300,000                      
Revenue Recognition Milestone Method Payments Due     14,900,000                      
Maintenance Costs     50,000                      
Cs Technology License [Member]                            
Payment Of Upfront Fees     600,000                      
Revenue Recognition Milestone Method Payments Due     14,900,000                      
Maintenance Costs     50,000                      
IL13Ra2 [Member]                            
Research and Development Expense                     $ 1,400,000      
Harvard College License [Member]                            
Payment Of Upfront Fees   $ 300,000                        
Other Commitment, Due in Next Twelve Months   25,000                        
Other Commitment, Due in Third Year   100,000                        
Other Commitment, Due in Second Year   50,000                        
Development Milestones Method Additional Payments Due   $ 16,700,000                        
CD123 CRA [Member]                            
Research and Development Expense                     $ 1,400,000      
Stephen Forman [Member]                            
Annual Consulting Fees                       $ 60,000    
Christine Brown [Member]                            
Annual Consulting Fees                       60,000    
University of California [Member]                            
Development Milestones Method Additional Payments Due         $ 14,300,000                  
University of California [Member] | UCLA License [Member]                            
Payment Of Upfront Fees         200,000                  
Other Commitment, Due in Next Twelve Months         15,000                  
Other Commitment, Due in Fifth Year         50,000                  
Other Commitment, Due in Fourth Year         $ 25,000                  
City Of Hope [Member]                            
Revenue Recognition Milestone Method Payments Due           $ 100,000                
Stock Issued During Period, Shares, Purchase of Assets                     293,588      
Payments for Other Fees       $ 100,000                    
City Of Hope [Member] | Intellectual Property [Member]                            
Payment Of Upfront Fees               $ 2,000,000            
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners                 10.00%          
Stock Issued During Period, Shares, Purchase of Assets                 1,000,000          
City Of Hope [Member] | Intellectual Property [Member] | Maximum [Member]                            
Royalty Expense                 $ 1,000,000          
City Of Hope [Member] | Commitment One [Member] | Intellectual Property [Member]                            
Development Milestones Method Additional Payments Due                 2,000,000          
City Of Hope [Member] | Commitment Two [Member] | Intellectual Property [Member]                            
Development Milestones Method Additional Payments Due                 14,500,000          
City Of Hope [Member] | AR CD123 License [Member]                            
Payment Of Upfront Fees           19,450                
Revenue Recognition Milestone Method Payments Due           14,500,000                
Research And Development Expense, Sponsored Research Payment           200,000                
Research and Development Expense                     $ 0      
Licensing Arrangements Additional Costs Incurred           97,490                
Maintenance Costs           25,000                
City Of Hope [Member] | IL License [Member]                            
Revenue Recognition Milestone Method Payments Due           14,500,000                
Maintenance Costs           25,000                
City Of Hope [Member] | Her2 Technology License [Member]                            
Payment Of Upfront Fees     600,000                      
Revenue Recognition Milestone Method Payments Due     14,900,000                      
Maintenance Costs     $ 50,000                      
City Of Hope [Member] | Spacer License [Member]                            
Maintenance Costs           10,000                
City Of Hope [Member] | IL13Ra2 [Member]                            
Payment Of Upfront Fees           9,300                
Research And Development Expense, Sponsored Research Payment           200,000                
Research and Development Expense                     0      
Licensing Arrangements Additional Costs Incurred           $ 100,000                
City Of Hope [Member] | Sponsored Research Agreement [Member]                            
Research and Development Expense                 $ 2,000,000 $ 1,500,000 2,000,000 $ 2,000,000    
Fred Hutchinson Cancer Research Center [Member] | CD20 Technology License [Member]                            
Payment Of Upfront Fees $ 300,000                          
Maintenance Costs 50,000                          
Development Milestones Method Additional Payments Due 39,100,000                          
Fred Hutchinson Cancer Research Center [Member] | CD20 Clinical Agreement [Member]                            
Research And Development Expense, Sponsored Research Payment $ 5,300,000                          
Research and Development Expense                     $ 600,000      
Common Class A [Member]                            
Stock Issued During Period, Shares, Purchase of Assets                   1,000,000 0      
Common Stock, Shares, Outstanding                     1,000,000 1,000,000    
Noncontrolling Interest, Ownership Percentage by Parent                     5.00%      
Stock Issued During Period, Value, Purchase of Assets                   $ 0 $ 0      
Common Stock, Shares Authorized                       1,000,000   1,000,000
Common Class A [Member] | City Of Hope [Member]                            
Stock Issued During Period, Shares, Purchase of Assets             293,588              
Common Class A [Member] | City Of Hope [Member] | Market Approach Valuation Technique [Member]                            
Stock Granted During Period, Value Per Share Determined             $ 5.73              
Stock Issued During Period, Value, Purchase of Assets             $ 1,700,000              
Common Class A [Member] | City Of Hope [Member] | Intellectual Property [Member]                            
Research and Development Expense                   $ 100,000        
Stock Granted During Period, Valuation Inputs, Weighted Marketability Rate                 44.80%          
Stock Granted During Period, Valuation Inputs, Weighted Average Cost of Capital                 30.00%          
Common Class A [Member] | City Of Hope [Member] | Intellectual Property [Member] | Discounted Cash Flow Model [Member]                            
Stock Granted During Period, Value Per Share Determined                 $ 0.147          
Stock Issued During Period, Value, Purchase of Assets                 $ 100,000